B7-33 is a relaxin-derived research peptide studied almost entirely in cell and animal models. This page describes hypothesized and investigational effects, not established treatments.
Overview
B7-33 is a single-chain peptide engineered from H2 relaxin, a hormone associated with tissue remodeling and connective-tissue softening. Because it was designed to retain relaxin's anti-fibrotic signaling in a simpler structure, most research interest centers on:
- Engaging the relaxin receptor RXFP1 rather than supplying full relaxin.
- Signaling through the ERK1/2 pathway linked to reduced tissue scarring.
- Whether a narrower signaling profile could be a useful research tool.
These are the mechanisms researchers study; they are not a promise of any clinical, cosmetic, or performance result.
Anti-fibrotic signaling
Fibrosis is the accumulation of excess scar-like extracellular matrix in tissue. In preclinical work, B7-33 has been examined for its ability to engage RXFP1 and promote signaling associated with slowing or reversing that matrix build-up. The recurring theme is biased signaling: activating a remodeling-related pathway while apparently sparing some of relaxin's other outputs.
- Anti-fibrotic effects are inferred from receptor and pathway activity.
- Effect size varies by model, tissue, and experimental conditions.
- Signaling activity in a dish does not guarantee a whole-body outcome.
Organ and disease models
Researchers have explored B7-33 in laboratory models of fibrosis affecting the heart, lung, and kidney, and in models related to preeclampsia. These settings are used because each involves abnormal tissue remodeling, which is the biology relaxin-derived peptides are thought to influence. Any interest in B7-33 for these areas comes from mechanism and animal data, not from controlled human trials.
How B7-33 compares to relaxin
B7-33 is best understood in relation to its parent hormone:
- Full H2 relaxin — a two-chain hormone with broad signaling; harder to produce and study.
- B7-33 — a single-chain fragment designed to keep anti-fibrotic signaling in a simpler, more stable format.
The proposed advantage of B7-33 is a more focused signaling profile, but whether that translates into a practical benefit remains an open research question.
Evidence and caveats
B7-33 has interesting preclinical signaling data, but that is not the same as proven benefit for any condition. Key caveats:
- It is not an approved therapy in the United States or elsewhere.
- Evidence is animal- and cell-based; human data are essentially absent.
- Anti-fibrotic activity in a model does not guarantee a clinical result.
- Long-term safety in people has not been established.